V体育官网 - Therapeutic C3 inhibitor Cp40 abrogates complement activation induced by modern hemodialysis filters
- PMID: 25468722
- PMCID: "V体育ios版" PMC4355228
- DOI: 10.1016/j.imbio.2014.10.026
"VSports注册入口" Therapeutic C3 inhibitor Cp40 abrogates complement activation induced by modern hemodialysis filters
Abstract (VSports注册入口)
Approximately 350,000 individuals in the United States rely on maintenance hemodialysis treatment because of end-stage renal disease. Despite improvements in dialysis technology, the mortality rate for patients treated with maintenance dialysis is still exceptionally high, with a 5-year survival rate of only 35%. Many patients succumb to conditions resulting at least in part from the chronic induction of inflammation. Among the triggers of inflammation, the complement system is of particular importance, being a well-appreciated mediator of inflammatory processes that is involved in many pathologic states. Here we used a refined pre-clinical model of hemodialysis in cynomolgus monkeys to confirm that even modern, polymer-based hemodialysis filters activate complement and to evaluate the potential of Cp40, a peptidic C3 inhibitor, to attenuate hemodialysis-induced complement activation. Our data show marked induction of complement activation even after only a single session of hemodialysis. Importantly, complete inhibition of complement activation was achieved in response to two distinct Cp40 treatment regimens. Further, we show that application of Cp40 during hemodialysis resulted in increased levels of the anti-inflammatory cytokine IL-10, indicating that Cp40 may be a potent and cost-effective treatment option for attenuating chronic inflammatory conditions in dialysis-dependent patients. VSports手机版.
Keywords: C3; Complement; Compstatin; Cp40; Hemodialysis V体育安卓版. .
Copyright © 2014 Elsevier GmbH V体育ios版. All rights reserved. .
Figures
References
-
- Bologa RM, Levine DM, Parker TS, Cheigh JS, Serur D, Stenzel KH, Rubin AL. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am. J Kidney Dis. 1998;32:107–114. - PubMed (VSports)
-
- Cavalli A, Del Vecchio L, Manzoni C, Locatelli F. Hemodialysis: yesterday, today and tomorrow. Minerva. Urol. Nefrol. 2010;62:1–12. - PubMed
-
- Chi ZL, Yoshida T, Lambris JD, Iwata T. Suppression of drusen formation by compstatin, a peptide inhibitor of complement C3 activation, on cynomolgus monkey with early-onset macular degeneration. Adv. Exp. Med. Biol. 2010;703:127–135. - PMC (VSports最新版本) - PubMed
-
- Ekdahl KN, Lambris JD, Elwing H, Ricklin D, Nilsson PH, Teramura Y, Nicholls IA, Nilsson B. Innate immunity activation on biomaterial surfaces: a mechanistic model and coping strategies. Adv. Drug Deliv. Rev. 2011;63:1042–1050. - PMC (VSports) - PubMed
Publication types
MeSH terms
- "V体育ios版" Actions
- Actions (VSports注册入口)
- Actions (VSports手机版)
- Actions (V体育2025版)
- "VSports app下载" Actions
- Actions (V体育2025版)
- "VSports最新版本" Actions
- "VSports在线直播" Actions
- VSports注册入口 - Actions
- Actions (V体育官网)
Substances (VSports)
- V体育ios版 - Actions
Grants and funding
LinkOut - more resources (VSports在线直播)
Full Text Sources (V体育安卓版)
Other Literature Sources
Medical
Miscellaneous
